Synbiotic Approach to Immunity and Metabolism in the Elderly Study
- Conditions
- Healthy
- Registration Number
- NCT03168503
- Lead Sponsor
- University of Roehampton
- Brief Summary
The aging process leads to a marked decline in immune function (immunosenescence), causing a significant reduction in immune response after vaccination or infections. Dietary intervention is an attractive, safe and non-invasive way to impact on gut bacteria and subsequently the functioning of the immune system. The ability of the dietary supplementation to alter these functions can be of particular importance in those groups that have an underdeveloped, poorly functioning immune system such as infants, immuno-compromised subjects or elderly. Research over the past two decades has provided evidence that administration of probiotics (live microorganisms which, when administered in adequate amounts, confer a health benefit on the host) could enhance immune function. Lactobacilli and bifidobacteria are the most common probiotics used in humans and various strains have been shown to have immunostimulatory properties in vitro and in experimental models, these properties include modulation of cytokine production. evidence exists of the immunostimulating effects of certain probiotics and the potential to use prebiotics to increase the levels of beneficial bacteria (which are known to be reduced in elderly population). Furthermore, by providing a probiotic at the same time as a prebiotic conditions for survival are enhanced. To date, only a small number of studies conducted have been randomised and/or placebo controlled to unequivocally demonstrate efficacies.
- Detailed Description
The aim of this study is to investigate the effect of probiotic Lactobacillus rhamnosus GG (commercialised as LGG), a pilus-less derivative L. rhamnosus GG (LGG-PB12)combined with a putative prebiotic PromitorTM (soluble corn fiber) i.e. a synbiotics and PromitorTM (SCF alone) on the faecal microbiota composition, metabolism and immunity in healthy individuals aged 60-80 years.
It consists of a 3 week randomised intervention treatment periods with the synbiotics, prebiotic and placebo control. Any adverse medical events which occur during the trial (e.g. headache, gut symptoms) should be recorded in a diary along with medication taken.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 40
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Primary Outcome Measures
Name Time Method The modulation of the gut microbiota by synbiotics and PromitorTM inflammatory/immune biomarkers Changes from baseline to 21 days synbiotics and PromitorTM treatment Fecal16S rRNA amplicon sequencing to assess changes in fecal bacterial abundance and species diversity
- Secondary Outcome Measures
Name Time Method The modulation of immune function by synbiotics and PromitorTM Changes from baseline to 21 days synbiotics and PromitorTM treatment Blood samples analysis to assess changes in cytokines production
Trial Locations
- Locations (1)
Department of Food and Nutritional Sciences, University of Reading
🇬🇧Reading, United Kingdom
Department of Food and Nutritional Sciences, University of Reading🇬🇧Reading, United Kingdom